Dolutegravir pharmacokinetics in Ugandan patients with TB and HIV receiving standard-versus high-dose rifampicin
Dolutegravir pharmacokinetics in Ugandan patients with TB and HIV receiving standard-versus high-dose rifampicin
ArticleAuthors: Allan Kengo, Ruth Nabisere, Kamunkhwala Gausi, Joseph Musaazi, Allan Buzibye, Denis Omali, Rob Aarnoutse, Mohammed Lamorde, Kelly E Dooley, Derek James Sloan, Paolo Denti, Christine Sekaggya-Wiltshire